Skip to main content

Recent News & Research


Biomarkers in NSCLC

*April 2022* In this video, EGFR Resisters co-founder Ivy Elkins does an interview with Rasheda Persinger, MedOnc Nurse Practioner for JADPRO’s Biomarkers in NSCLC Resource Center. It covers how to best discuss biomarker testing, treatments and symptoms with patients diagnosed with lung cancer. Your healthcare team should use clear, understandable…

ODAC Recommends New Trial Data of Sintilimab in US Population of Frontline NSCLC

*February 2022* The FDA’s Oncologic Drugs Advisory Committee voted against using single-country foreign data to support a biologics license application (BLA) for sintilimab injection plus pemetrexed and platinum-based chemotherapy for the frontline treatment of patients with nonsquamous non–small cell lung cancer (NSCLC). ODAC concluded that supporting data from the phase…

INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance

*December 2021* Osimertinib is used to treat a type of lung cancer that has specific changes (mutations) in a gene called EGFR. Although tumors will usually shrink (respond) during treatment with osimertinib, they can stop responding, or become resistant, to osimertinib. A common cause of resistance is ‘MET amplification’, which…

Slide Decks from the 2022 Targeted Therapies Meeting

*February 2022* Open Questions Around First-Line Treatment for EGFR Mutant Lung Cancers, Dr Helena Yu, presenter Acquired Resistance to EGFR TKIs, Dr. Katerina Politi, presenter Histological transformation and off target mechanisms are frequently identified on disease progression for patients with EGFRmutant lung cancer treated with first-line osimertinib, Dr. Noura Choudhury,…
March 18, 2022